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Abstract 
In contrast to the majority of allergic or hypersensitivity conditions, worldwide anaphylaxis epidemiological data 
remain sparse with low accuracy, which hampers comparable morbidity statistics. Data can differ widely depending 
on a number of variables. In the current document we reviewed the forms on which anaphylaxis has been defined 
and classified; and how it can affect epidemiological data. With regards to the methods used to capture morbidity 
statistics, we observed the impact of the anaphylaxis coding utilizing the World Health Organization’s International 
Classification of Diseases. As an outcome and depending on the anaphylaxis definition, we extracted the cumulative 
incidence, which may not reflect the real number of new cases. The new ICD‑11 anaphylaxis subsection develop‑
ments and critical view of morbidity statistics data are discussed in order to reach new perspectives on anaphylaxis 
epidemiology.
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Anaphylaxis epidemiology: open introductory 
questions
Anaphylaxis has been defined for clinical use by health-
care professionals as a serious, generalized, allergic or 
hypersensitivity reaction that can be life-threatening and 
even fatal [1–3]. In contrast to the majority of allergic or 
hypersensitivity conditions such as asthma or rhinitis, 
accurate worldwide anaphylaxis epidemiological data 
remain lacking for harmonization. Data can differ widely 
depending on a number of variables. For instance, Euro-
pean data have indicated incidence rates for all-cause 
anaphylaxis ranging from 1.5 to 7.9 per 100,000 person/
year, with an estimate that 0.3% (95% CI 0.1–0.5) of the 
population will experience anaphylaxis at some point 
during their lifetime [4]. As well, it is estimated that 1 in 
every 3000 inpatients in US hospitals suffer from an ana-
phylactic reaction [5].
Although available data, specifically those collected 
during the past decade, show an increased frequency 
of anaphylaxis, there are still challenges in interpreting 
these informations [6, 7] and its global applicability. The 
most widely discussed issues in the epidemiology of ana-
phylaxis filed over the last 10 years are: (I) regional varia-
tions in concepts and definitions (Fig. 1) [1–3, 8–10], (II) 
whether prevalence or incidence is the best measure of 
the frequency of anaphylaxis in the general population, 
(III) whether the frequency of anaphylaxis is higher than 
previously thought, and (IV) whether the increasing inci-
dence published is real or reflects different methodolo-
gies and definitions used.
Over the last several years, an increasing number of 
clinical databases have been developed to capture reli-
able anaphylaxis epidemiological data at both national 
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and regional levels (Fig.  2). However, a substantial pro-
portion of the current data on the epidemiology of ana-
phylaxis has come from registries with limited scope and 
population source. Different methods have been applied 
in an attempt to reach reliable epidemiological data, but 
most of the studies have focused on specific triggers or 
at-risk populations. Lack of harmonized strategies to 
record anaphylaxis cases hampers collection of compara-
ble epidemiological data. In general, registries are repre-
sentative sources to reach epidemiological data, and are 
applied only if the reporting of the conditions is manda-
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On the other hand, broad population-based studies 
allow descriptive and analytic epidemiological analy-
sis covering the general population and identify all 
or a known fraction of the cases in a particular com-
munity. Generally speaking, population-based studies 
have adopted the World Health Organization (WHO) 
International Classification of Diseases (ICD) as the 
main tool to capture the proposed outcomes. These 
studies have been especially useful in detailing time-
related trends, capturing clinical practice and principal 
discharge diagnosis coding statistics, and in providing 
broader morbidity and mortality statistics (MMS). How-
ever, anaphylaxis has never been well classified under 
the ICD context, either for morbidity [11] (Table  1) or 
for mortality data [12]. This is exemplified by the under-
notification of anaphylaxis deaths using the Brazilian 
national mortality database [12]. An important reason 
for this is the difficulty of coding anaphylaxis fatalities 
under the WHO ICD system. In most countries, mor-
tality statistics are routinely compiled according to reg-
ulations and recommendations adopted by the World 
Health Assembly (WHA). Causes of deaths are classi-
fied and grouped according to the ICD edition in use 
at the time and the information on death certificates is 
collected using the international form recommended by 
the WHO. However, a limited number of ICD-10 codes 
are considered to be valid for representing underlying 
causes of death on the current death certificates, and 
with regard to anaphylaxis as such, there are simply no 
valid codes [12].
Taking the opportunity presented by the ongoing ICD-
11 revision, the under-notification of death data [12] 
triggered a cascade of strategic international actions 
supported by the Joint Allergy Academies and the ICD 
WHO governance [11–23] to update the classifications of 
allergic conditions for the new ICD edition. These efforts 
have resulted in the construction of the new “Allergic and 
hypersensitivity conditions” section built under the “Dis-
orders of the Immune system” chapter [17, 24].
In order to better delineate the proposed changes and 
follow the ICD-11 revision agenda, we reviewed the 
forms on which anaphylaxis has been defined and classi-
fied, and the published anaphylaxis epidemiological data, 
particularly with regards to the methods used to capture 
morbidity statistics.
Anaphylaxis: reaching answers based on definition 
and classification
Anaphylaxis definition impacts in epidemiological data
All anaphylaxis guidelines [1–3, 8–10] have consist-
ently defined anaphylaxis as a severe life-threatening 
generalized or systemic hypersensitivity reaction. Being 
described as a reaction implies a risk of overestimating 
the prevalence of anaphylaxis. For some conditions, such 
as asthma, the number of patients with the condition is 
different from the number of (asthma) exacerbations 
(Fig.  3a). However, using the definition of anaphylaxis, 
the number of exacerbations (reactions) can be wrongly 
taken as the number of cases (disease) (Fig. 3b), resulting 
in an overestimated lifetime cumulative incidence.
Incidence is the measure of the frequency of a new case 
(or condition) in a population at risk within a period of 
time. Therefore, given that anaphylaxis is an acute con-
dition with long asymptomatic periods during which the 
risk of relapse can decrease over time in some patients 
or when culprit factors such as allergens are avoided or 
counteracted (e.g. stinging insect venom immunother-
apy), knowing the number of new episodes (incidence) 
over a specific period can not be an adequate measure 
of frequency. Cumulative incidence, also known as inci-
dence proportion may be not an adequate measure for 
frequency of anaphylaxis, since the reaction is no longer 
active once the episode is resolved. For this reason, more 
detailed data on recurrent episodes are required to over-
come this challenge in anaphylaxis epidemiology studies.
Updated anaphylaxis classification and coding in the ICD
The ICD is the broadest classification and coding system 
used to monitor the incidence and prevalence of diseases 
and other health problems, reflecting the general health 
situation in countries and populations [25].
Taking the example of the ICD-10 (2016 version) [26], 
anaphylaxis has been classified under the “XIX Injury, 
poisoning and certain other consequences of external 
causes” chapter, specifically the “T78 Adverse effects, not 
elsewhere classified” section. Under this section, differ-
ent hypersensitivity conditions are classified at the same 
level, such as “Anaphylactic shock due to adverse food 
reaction”, “Angioneurotic oedema” and “Allergy, unspeci-
fied” (Table 1), reflecting a misunderstanding of concepts 
used by the health care professionals on a daily basis.
The construction of the new ICD-11 section address-
ing to allergic and hypersensitivity conditions now allows 
anaphylaxis to be properly classified and attaining greater 
visibility within ICD (Table 1). Currently, this subsection 
contains 7 main anaphylaxis headings to be combined 
with severity and causality classification/specifications. 
The building process of this framework resulted from 
combined efforts and constant discussions with the 
groups of experts and the ICD WHO governance.
The construction of the new subsection addressed to 
anaphylaxis means that it will now be recognized as a 
clinical condition requiring specific documentation and 
management.
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Lessons from population‑based anaphylaxis morbidity 
epidemiology publications
From 19th to 26th October 2016, 1896 manuscripts 
were selected using PubMed Mesh terms “anaphylaxis 
epidemiology”, “epidemiology of anaphylaxis” or “ana-
phylaxis epidemiology population-based studies”. After 
removing those published before 2011 and those not 
published in English, there were 532 papers published in 
the last 5  years. We did not include case reports, stud-
ies in animal models, quality of life studies, fatality stud-
ies, guidelines or reviews (Fig.  4). All publications were 
independently evaluated by two co-authors and disa-
greements related to the inclusion into the analysis were 
resolved through open discussion and consensus.
We analyzed methodological aspects, main outcomes 
and databases used in the remaining 15 publications 
selected as eligible according to the selection criteria 
(Fig. 4) from different countries. The methods used and 
the definitions taken varied among the publications; 
however, 67% focused on rates of hospitalization or 
emergency department admissions. National databases 
were used in 67% of the studies. Overall, 40% were large 
population-based studies and 100% of these documents 
used the ICD definition as the starting point of the analy-
sis (Table  2). Based on ICD registries, regardless of the 
ICD version used, 71% of all the studies had to utilize 
secondary data in order to capture the anaphylaxis data, 
meaning that the data have been affected by the misclas-
sification of anaphylaxis in the previous versions of the 
ICD.
Most of the studies (60%) did not address the possibil-
ity of recurrence of episodes, and, therefore, of cumula-
tive incidence. This highlights the need to distinguish 
the number of patients with anaphylaxis per year from 
the number of episodes per year. Even with the alterna-
tive strategy of reaching the mean number of anaphylaxis 
cases within a started time, data would be influenced by 
the methodology and definitions applied. In other words, 
most of epidemiological studies considering incidence as 
the main variable may be overestimating the number of 
anaphylactic patients. True frequency of anaphylaxis is 
also possibly underestimated due to under-recognition 
by patients and caregivers and under-diagnosis by health 
care professionals (e.g.: difficulty on diagnosing anaphy-
laxis in the absence of hypotension or shock).
Reaching new perspectives for anaphylaxis 
epidemiology
In this manuscript, we provide arguments for the need of 
reviewing the current definitions in use for anaphylaxis. 
The definitions are able to directly impact in the epidemi-
ology of anaphylaxis as a disease. Incorporating refined 
strategies to achieve accuracy and comparable MMS can 
support public health changes to reach better patients’ 
care and prevention worldwide.
Due to recent achievements at the international level 
on enhancing terminology, classification, definitions 
and coding of allergic and hypersensitivity conditions 
through the ongoing WHO ICD revision process, ana-
phylaxis is now considered a condition. Importantly the 
Table 1 Anaphylaxis classification and coding in ICD-10 
and in ICD-11
Anaphylaxis ICD‑10 codes (2016 ver‑
sion)
Anaphylaxis ICD‑11 codes 
(November 2016 version)
Chapter XIX injury, poisoning and certain 
other consequences of external causes 
(S00–T98)
Chapter 04 disorders of the 
immune system
Other and unspecified effects of external 
causes (T66–T78)
Section allergic and hyper‑
sensitivity conditions
T78 Adverse effects, not elsewhere clas‑
sified
Note: This category is to be used as the 
primary code to identify the effects, 
not elsewhere classifiable, of unknown, 
undetermined or ill‑defined causes. For 
multiple coding purposes this category 
may be used as an additional code to 
identify the effects of conditions classi‑
fied elsewhere
Subsection anaphylaxis
 T78.0 Anaphylactic shock due to adverse 
food reaction
4B50 Anaphylaxis due to 
allergic reaction to food




 T78.2 Anaphylactic shock, unspecified 4B52 Anaphylaxis due to 
insect venom
  Allergic shock NOS 4B53 Anaphylaxis provoked 
by physical factors
  Anaphylactic reaction     4B53.1 Exercise‑induced 
anaphylaxis
  Anaphylaxis     4B53.2 Cold‑induced 
anaphylaxis
 T78.3 Angioneurotic oedema     4B53.Y Anaphylaxis pro‑
voked by other speci‑
fied physical factors
  Giant urticaria     4B53.Z Anaphylaxis pro‑
voked by unspecified 
physical factors
  Quincke oedema 4B54 Anaphylaxis due to 
inhaled allergens
 T78.4 Allergy, unspecified 4B55 Anaphylaxis due to 
contact with allergens
4B56 Anaphylaxis secondary 
to mast cell disorder
  Allergic reaction NOS
  Hypersensitivity NOS 4B5Y Other specified ana‑
phylaxis
  Idiosyncracy NOS




 T78.9 Adverse effect, unspecified
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new classification system for anaphylaxis will surely ena-
ble the collection of more accurate epidemiological data 
to support quality management of patients with allergies, 
better health care planning and decision-making and 
public health measures to reduce the morbidity and mor-
tality attributable to anaphylaxis.
Based on current developments, reviewing the defi-
nition of anaphylaxis and epidemiology strategies by 
clarifying differences between anaphylaxis episodes 
(reactions) from anaphylaxis as a condition itself will lead 
to more precision on MMS. Cumulative incidence is an 
inadequate measure here, since the reaction is no longer 
active once the episode is resolved and one patient can 
present different episodes of anaphylactic reactions in 
his/her life. Most of the publications have so far consid-
ered the episodes (illness), regardless to the subject suf-
fering of this condition (patient). A possible strategy in 
order to avoid cumulative incidence of anaphylaxis would 
be reaching recurrence of anaphylactic episodes. Con-
sistent scientific, economical and political changes may 
follow this move, which will likely be reflected in better 
management of patients with anaphylaxis worldwide. 
For instance, precise and broader anaphylaxis MMS will 
support the global availability of auto-injectable adrena-
line, currently available in less than 35% of all countries 
[23]. Specific focus in the patients’ care, and not just in 
the episodes, would also support primary and secondary 
prevention actions.
As demonstrated, anaphylaxis regional epidemiological 
data differ considerably according to many variables and 
it is still unclear whether the increasing incidence pub-
lished is real or the results reflect different methods used 
to define and characterize anaphylaxis. However, based 
on current statistics [4, 5], severe anaphylaxis fits well the 
definition of a rare disease. Conceptually, rare diseases 
can be defined as life-threatening or chronic debilitat-
ing disorders, which are of low prevalence and typically 
require a multi-disciplinary approach to address preven-
tion and treatment. The Orphanet, lead by the French 
National Institution of Health and Medical Research 
(INSERM) and the French Ministry of Health, is respon-
sible for developing an inventory of rare diseases and a 
classification system which could serve as a template to 
update International terminologies. When the WHO 
launched the revision process of the ICD, a rare dis-
eases Topic Advisory Group was established. So far 5400 
rare diseases listed in the Orphanet database have an 
endorsed representation in the foundation layer of ICD-
11 [27, 28], but severe anaphylaxis is not yet included 
on the list. In addition to all the benefits expected by 
the actions to update terminology, definitions and clas-
sification of allergic and hypersensitivity conditions 













Fig. 3 General model to explain how definitions of allergic conditions can affect prevalence data (a asthma as a model, b anaphylaxis as a model)
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anaphylaxis is a public health priority, therefore in order 
to strengthen awareness and quality clinical management 
of patients it should therefore be formally added to the 
list of rare diseases. Including severe anaphylaxis into the 
list of rare diseases may allow, in first instance, the allo-
cation of resources to better understand the national and 
global epidemiology of anaphylaxis as a disease; monitor 
the patterns of this disorder to follow hospitalizations, 
mortality, avoidable deaths and costs. Having more pre-
cise epidemiological data may support the global availa-
bility of adrenaline auto-injectors worldwide at affordable 
price addressed to the patients’ care through argumenta-
tion with national bodies and stakeholders. For instance, 
the French Ministry of Health, in coordination with the 
State Secretariat for Higher Education and Research, 
implements a proactive policy based on the mobilization 
of health/research professionals and patients’ associa-
tions in order to improve quality diagnosis, management 
and prevention of the 3 million patients affected by rare 
diseases in France. This health intervention/policy model 
can be took as an example in different countries in order 
to implement essential actions according to individual 
national needs, such as the availability of adrenaline auto-
injectors in low incoming countries [23].
Anaphylaxis epidemiological publications are also 
hampered by the inclusion of all severity degrees of 
Fig. 4 Anaphylaxis epidemiology publications eligibility selection process
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anaphylaxis. Mild reactions in which manifestations are 
generally limited to one organ or system, such as the 
skin, usually do not incur any risk of death. The inclusion 
of these cases in the epidemiological studies provides 
mistaken perception of high and increasing incidence 
of severe anaphylaxis. Our focus would be addressing 
severe reactions in which the risk of mortality is strong 
and requires additional prevention measures and a coor-
dinated management such as the one provided by the 
rare disease network in our country. To date, there is 
no available data regarding severe cases of anaphylaxis 
in Europe. French data suggests that less than 30,000 
people are affected by severe anaphylaxis and, 9.2 per 
100,000 person-years based on the University Hospital of 
Montpellier data [29]. Australian data demonstrated the 
increasing number of patients at risk of anaphylaxis, from 
0.98% in 2009 reaching 1.38% in 2014 in school aged chil-
dren. In contrast, the number of adrenaline auto-injec-
tors activated (severe cases) per year per 1000 students at 
risk of anaphylaxis was 6 and 8 in 2010 and 2014 respec-
tively [30]. If taken as isolated data of patients at risk, it 
can drive readers to think that anaphylaxis is increasing 
in this country. However, the administration of the treat-
ment as objective data indicates that severe anaphylaxis 
can be considered as rare disease.
The ICD-11 intends will be presented to the WHA in 
2018. A known issue regarding accurate epidemiologi-
cal data and miscoding is the lack of training regarding 
how disorders should be classified and coded in admin-
istrative and institutional databases. For this reason, the 
core ALLERGY in ICD-11 operational team (LKT, PD) 
in collaboration with the WHO and with the support of 
our international academies network, intends to imple-
ment education tools to support the allergy community 
in the transition process, preparing health professionals 
and stakeholders for the new logic of the ICD-11, when it 
is launched. Educational efforts will also help to decrease 
the under-recognition of anaphylaxis by patients, car-
egivers, and health professionals, health authorities and 
governments and have been the main aim of allergy acad-
emies by promoting education programs and publica-
tions in the field.
The construction of the new section dealing with ana-
phylaxis means that the latter will now be recognized as 
a clinical condition requiring specific documentation and 
management. Besides increasing the accuracy and sensi-
tivity of clinical diagnosis data, unifying the allergic and 
hypersensitivity conditions into a single section of the 
ICD, endorsed by the WHO ICD governance bodies can 
be considered a strong epidemiological, economical and 
political move that advocates to optimal diagnosis and 
management of allergic patients worldwide. By allowing 
all the relevant diagnostic terms for anaphylaxis to be 
included into the ICD-11 framework, WHO has recog-
nized their importance not only to clinicians but also to 
epidemiologists, statisticians, health care planners and 
other stakeholders. In the current manuscript we raise 
awareness of the outcomes of the ongoing ICD revision 
process as an instrument that has been developed to 
provide more precise anaphylaxis MMS to ensure com-
parability in monitoring, decision-making and achieving 
quality clinical practice. Meanwhile we propose strategies 
to improve anaphylactic patients’ care through reviewing 
definitions and epidemiological data. This document and 
critical view intend to support national and international 
health interventions and health policy changes.
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